Acambis appoints David Lawrence as CFO
Acambis plc ("Acambis') announces the appointment of David Lawrence as Chief Financial Officer.
Mr Lawrence, 41, is currently Vice President of Finance for Chiron Vaccines, the vaccines division of Chiron Corporation ('Chiron'), which he joined in February 2002. In that role, he is responsible for all aspects of finance and accounting for Chiron Vaccines, and also for strategic planning, business development, mergers and acquisitions. In particular, he played a lead role in Chiron's acquisition of PowderJect Pharmaceuticals plc and the subsequent disposal of various non-core assets/businesses. Chiron Vaccines is the fifth largest vaccines business in the world and had revenues of nearly $700m in 2003.
Prior to Chiron Vaccines, the majority of David's career has been spent with GlaxoSmithKline plc and its predecessor companies. He joined in 1988 as a Finance graduate trainee and progressed through a number of senior roles in Finance, Information Management and Distribution to become Head of UK Finance and Senior Vice President of Financial Management in Research and Development. He left GSK in 2001 to become Chief Financial Officer of Strakan Pharmaceuticals, a privately held biotechnology company, before joining Chiron Vaccines.
David is expected to join Acambis in the next few weeks and will be based at Acambis' Cambridge, UK offices. His appointment follows the promotion of the previous Chief Financial Officer, Gordon Cameron, to Chief Executive Officer earlier this year.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
